论文部分内容阅读
胰高血糖素样肽-1(Glucagon-Like Peptide-1,GLP-1)受体激动剂类药物是一类新型抗糖尿病药物,可呈血糖依赖性地促进胰岛素的分泌、减慢胃排空、增加外周组织对葡萄糖的摄取,从而起到控制血糖的作用。本文对GLP-1受体激动剂近年来的国内外文献进行综述,从其对血糖、血脂及体质量等方面的影响展开分析,并比较了不同GLP-1受体激动剂之间,及与其他降糖药物之间的疗效差异,旨在阐明此类药物在改善2型糖尿病代谢方面的作用特点。
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists are a new class of antidiabetic drugs that promote insulin secretion in a blood glucose-dependent manner and slow down gastric emptying , Increase peripheral tissue glucose uptake, which play a role in controlling blood sugar. In this paper, GLP-1 receptor agonists in recent years at home and abroad are reviewed, from its impact on blood glucose, blood lipids and body mass analysis, and compared different GLP-1 receptor agonists, and with The differences in efficacy between other hypoglycemic agents are designed to elucidate the role of such agents in improving the metabolism of type 2 diabetes.